id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2008-D-0128-0001,FDA,FDA-2008-D-0128,Draft Guidance for Industry on Drug-Induced Liver Injury: Premarketing Clinical Evaluation; Reopening of Comment Period; Public Conference,Notice,NEC-Notice of Extension,2008-03-06T05:00:00Z,2008,3,2008-03-06T05:00:00Z,2008-07-01T03:59:59Z,2008-07-02T01:22:26Z,E8-04361,0,0,09000064803e9744
FDA-2008-D-0128-0002,FDA,FDA-2008-D-0128,Draft Guidance for Industry - Drug-Induced Liver Injury: Premarketing Clinical Evaluation,Other,Guidance,2008-03-06T05:00:00Z,2008,3,2008-03-06T23:35:27Z,2008-07-01T03:59:59Z,2016-01-06T18:51:41Z,,0,0,09000064803ea4f0